Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Go back to Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline| Gilead Sciences (NASDAQ: GILD) | Delayed: 124.87 +1.11 (0.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.76 | 52 Week High | $108.63 | |||
| Open | $124.30 | 52 Week Low | $71.39 | |||
| Day High | $125.17 | P/E | 68.99 | |||
| Day Low | $123.00 | EPS | $1.81 | |||
| Volume | 8,126,292 | |||||
